Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07284667 · ClinicalTrials.gov registry record · Phase 2

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

A Phase 2 study of Major Depressive Disorder (MDD) and Depressive Disorder, Treatment-Resistant, sponsored by ACADIA Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
153
Enrollment target
12
Study locations

NCT07284667 is a Phase 2 study of Major Depressive Disorder (MDD) and Depressive Disorder, Treatment-Resistant that is actively recruiting participants, run by ACADIA Pharmaceuticals. The registered enrollment target is 153 participants, roughly in line with the 152-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target. The trial reports 12 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07284667, a Phase 2 study of Major Depressive Disorder (MDD) and Depressive Disorder, Treatment-Resistant, is actively recruiting participants, sponsored by ACADIA Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
153 participants
Enrollment target
12
Study locations

Study Summary

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression? * What adverse events do participants have when taking ACP-211?

Conditions Studied

Major Depressive Disorder (MDD) Depressive Disorder, Treatment-Resistant

Interventions

  • DRUG Placebo
  • DRUG ACP-211

Study Locations (12)

Florida

  • Sandhill Research, LLC/DBA Accel Research Sites - Largo
  • Clinical Neuroscience Solutions, Inc. - Orlando
  • IPTB Clinical Research - Tampa

Texas

  • Dynamed Clinical Research LP d/b/a DM Clinical Research - Houston
  • Olympus Clinical Research, LLC - Katy

California

  • Inland Psychiatric Medical Group - Chino

Colorado

  • Mountain View Clinical Research - Denver

Massachusetts

  • Vitalix Clinical, Inc. - Worcester

Nevada

  • Redbird Research LLC - Las Vegas

New Jersey

  • CenExel Hassman Research Institute, LLC - Marlton

New York

  • Integrative Clinical Trials LLC - Brooklyn

Trial Details

FieldValue
Enrollment Target 153 participants
Start Date 2025-11-14
Est. Completion 2027-09
Phase Phase 2

Sponsor

ACADIA Pharmaceuticals

35 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07284667

The ClinicalTrials.gov registry entry for NCT07284667 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 152-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07284667 reports 12 study locations spanning 9 distinct geographic areas - top geographies include Florida, Texas, California.

Frequently Asked Questions

What is clinical trial NCT07284667 about?

NCT07284667 is a clinical study titled "ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response". The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work...

What is the current status of trial NCT07284667?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2025-11-14. Estimated completion is 2027-09.

What conditions does trial NCT07284667 study?

This clinical trial studies the following conditions: Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant.

What interventions are being tested in trial NCT07284667?

The interventions under investigation include: Placebo (DRUG), ACP-211 (DRUG).

Who is sponsoring clinical trial NCT07284667?

This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07284667 being conducted?

This trial has 12 study locations across California, Colorado, Florida, Massachusetts, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Major Depressive Disorder (MDD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Major Depressive Disorder (MDD)

All registered trials for this condition

Depressive Disorder, Treatment-Resistant

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.